22.53
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACAD Giù?
Forum
Previsione
Precedente Chiudi:
$22.62
Aprire:
$22.55
Volume 24 ore:
2.08M
Relative Volume:
1.00
Capitalizzazione di mercato:
$3.80B
Reddito:
$890.53M
Utile/perdita netta:
$30.57M
Rapporto P/E:
125.17
EPS:
0.18
Flusso di cassa netto:
$80.53M
1 W Prestazione:
+5.33%
1M Prestazione:
+5.68%
6M Prestazione:
+56.13%
1 anno Prestazione:
+52.85%
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Nome
Acadia Pharmaceuticals Inc
Settore
Industria
Telefono
858-558-2871
Indirizzo
12830 EL CAMINO REAL, SAN DIEGO
Confronta ACAD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
ACAD
Acadia Pharmaceuticals Inc
|
22.53 | 3.82B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
417.21 | 108.30B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
652.91 | 69.37B | 14.25B | 4.58B | 3.56B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.59 | 62.38B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
821.97 | 51.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.95 | 34.94B | 398.11M | -1.03B | -868.57M | -5.7032 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-21 | Iniziato | Citigroup | Buy |
| 2025-05-21 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2025-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | Iniziato | BMO Capital Markets | Outperform |
| 2024-03-12 | Downgrade | Mizuho | Buy → Neutral |
| 2024-03-12 | Reiterato | Needham | Buy |
| 2024-01-30 | Iniziato | Robert W. Baird | Outperform |
| 2024-01-24 | Aggiornamento | Needham | Hold → Buy |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-11-06 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-10-17 | Iniziato | UBS | Buy |
| 2023-10-10 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-01-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-11-04 | Downgrade | Goldman | Neutral → Sell |
| 2022-11-01 | Iniziato | Loop Capital | Hold |
| 2022-08-08 | Downgrade | Citigroup | Buy → Neutral |
| 2022-08-05 | Downgrade | Citigroup | Buy → Neutral |
| 2022-06-21 | Downgrade | Jefferies | Buy → Underperform |
| 2022-06-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-03-16 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-12-21 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-11-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Ripresa | Needham | Hold |
| 2021-06-10 | Iniziato | Berenberg | Hold |
| 2021-04-07 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | Downgrade | Goldman | Buy → Neutral |
| 2021-04-06 | Downgrade | Jefferies | Buy → Hold |
| 2021-04-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-05 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-03-09 | Downgrade | Citigroup | Buy → Neutral |
| 2021-03-09 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-03-09 | Reiterato | H.C. Wainwright | Buy |
| 2021-03-09 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | Downgrade | Stifel | Buy → Hold |
| 2020-12-16 | Iniziato | Mizuho | Buy |
| 2020-11-16 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-08-20 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-07 | Aggiornamento | Stifel | Hold → Buy |
| 2020-04-16 | Iniziato | Jefferies | Buy |
| 2020-03-31 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2019-12-16 | Iniziato | Guggenheim | Buy |
| 2019-10-24 | Iniziato | Oppenheimer | Perform |
| 2019-10-01 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-09-13 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | Reiterato | Needham | Buy |
| 2018-12-10 | Iniziato | Canaccord Genuity | Hold |
| 2018-09-21 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | Reiterato | Stifel | Hold |
| 2018-08-07 | Iniziato | Stifel | Hold |
| 2018-08-06 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
Mostra tutto
Acadia Pharmaceuticals Inc Borsa (ACAD) Ultime notizie
Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Why ACADIA Pharmaceuticals Inc. stock appeals to dividend seekers - newser.com
Why ACADIA Pharmaceuticals Inc. stock remains undervaluedMarket Sentiment Review & Community Trade Idea Sharing - newser.com
Ranking ACADIA Pharmaceuticals Inc. among high performing stocks via toolsRisk Management & Daily Growth Stock Tips - newser.com
Understanding ACADIA Pharmaceuticals Inc.’s price movementJuly 2025 Snapshot & Low Drawdown Momentum Trade Ideas - newser.com
Acadia Pharmaceuticals (NASDAQ: ACAD) to Join UBS and Jefferies Healthcare Conferences - Stock Titan
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences - Business Wire
Does Acadia (ACAD) Have the Potential to Rally 27.66% as Wall Street Analysts Expect? - sharewise.com
Is HCA HEALTHCARE (HCA) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Is ACADIA Pharmaceuticals Inc. stock a top momentum play2025 Geopolitical Influence & Long Hold Capital Preservation Plans - newser.com
How ACADIA Pharmaceuticals Inc. stock performs after earningsRecession Risk & Long-Term Safe Investment Plans - newser.com
How ACADIA Pharmaceuticals Inc. stock performs in high volatility marketsJuly 2025 Patterns & Reliable Volume Spike Alerts - newser.com
Real time alert setup for ACADIA Pharmaceuticals Inc. performanceIPO Watch & Long-Term Investment Growth Plans - newser.com
Is ACADIA Pharmaceuticals Inc. stock supported by strong fundamentalsMarket Risk Summary & Weekly Momentum Stock Picks - newser.com
Why ACADIA Pharmaceuticals Inc. stock is rated strong buyWeekly Volume Report & High Yield Equity Trading Tips - newser.com
ACADIA Pharmaceuticals Inc. stock trend outlook and recovery pathJuly 2025 Breakouts & Expert Approved Momentum Trade Ideas - newser.com
ACADIA Pharmaceuticals Advances Phase 2 Study of ACP-204 for Lewy Body Dementia Psychosis - TipRanks
Is ACADIA Pharmaceuticals Inc. stock trading near support levels2025 Macro Impact & Free Daily Entry Point Trade Alerts - newser.com
ACADIA Pharmaceuticals Advances Alzheimer’s Disease Psychosis Study with ACP-204 - TipRanks
Glioblastoma Multiforme Pipeline 2025: MOA and ROA Insights, - openPR.com
Glioblastoma Multiforme Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | InovioPharma, Pfizer, Roche, ACADIA Pharma, BioNTech, Oncotelic - Barchart.com
ACADIA’s ACP-204 Study: A Promising Step for Alzheimer’s Disease Psychosis Treatment - TipRanks
ACADIA Pharmaceuticals Advances Study on Carbetocin Nasal Spray for Prader-Willi Syndrome - TipRanks
ACADIA Pharmaceuticals Advances Phase 3 Study for Lewy Body Dementia Psychosis Treatment - TipRanks
Merger Talk: What catalysts could drive ACADIA Pharmaceuticals Inc. stock higherEntry Point & Fast Gaining Stock Strategy Reports - Fundação Cultural do Pará
Is ACADIA Pharmaceuticals Inc. reversing from oversold territoryEarnings Beat & Intraday High Probability Alerts - newser.com
How sentiment analysis helps forecast ACADIA Pharmaceuticals Inc.Jobs Report & Growth Focused Investment Plans - newser.com
Acadia Pharmaceuticals Inc Azioni (ACAD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):